SE9803761D0 - Method to avoid increased iridial pigmentation during prostaglandin treatment - Google Patents

Method to avoid increased iridial pigmentation during prostaglandin treatment

Info

Publication number
SE9803761D0
SE9803761D0 SE9803761A SE9803761A SE9803761D0 SE 9803761 D0 SE9803761 D0 SE 9803761D0 SE 9803761 A SE9803761 A SE 9803761A SE 9803761 A SE9803761 A SE 9803761A SE 9803761 D0 SE9803761 D0 SE 9803761D0
Authority
SE
Sweden
Prior art keywords
iridial pigmentation
avoid increased
prostaglandin treatment
pigmentation during
prostaglandin
Prior art date
Application number
SE9803761A
Other languages
Swedish (sv)
Inventor
Johan Stjernschantz
Bahram Resul
Original Assignee
Synphora Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synphora Ab filed Critical Synphora Ab
Priority to SE9803761A priority Critical patent/SE9803761D0/en
Publication of SE9803761D0 publication Critical patent/SE9803761D0/en
Priority to PCT/SE1999/001993 priority patent/WO2000025771A1/en
Priority to EP99971315A priority patent/EP1126835A1/en
Priority to JP2000579212A priority patent/JP2002528491A/en
Priority to AU14350/00A priority patent/AU758973B2/en
Priority to CA002349427A priority patent/CA2349427A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anti-inflammatory agents are used to prevent iridial pigmentation during prostaglandin treatment and to manufacture pharmaceuticals for this purpose. A method for preventing iridial pigmentation as well as a method for treating glaucoma is based on the concomitant or simultaneous administration of a prostaglandin or prostaglandin analogue and an anti-inflammatory agent. Both non-steroid and steroid anti-inflammatory agents can be employed according to the invention.
SE9803761A 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment SE9803761D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9803761A SE9803761D0 (en) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment
PCT/SE1999/001993 WO2000025771A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
EP99971315A EP1126835A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
JP2000579212A JP2002528491A (en) 1998-11-04 1999-11-04 How to prevent increased iris pigmentation during prostaglandin treatment
AU14350/00A AU758973B2 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
CA002349427A CA2349427A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803761A SE9803761D0 (en) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment

Publications (1)

Publication Number Publication Date
SE9803761D0 true SE9803761D0 (en) 1998-11-04

Family

ID=20413170

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803761A SE9803761D0 (en) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment

Country Status (6)

Country Link
EP (1) EP1126835A1 (en)
JP (1) JP2002528491A (en)
AU (1) AU758973B2 (en)
CA (1) CA2349427A1 (en)
SE (1) SE9803761D0 (en)
WO (1) WO2000025771A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
KR100627620B1 (en) * 1998-05-15 2006-09-25 와카모토 세이야꾸 가부시끼가이샤 Anti-inflammatory eye drops
WO2002005848A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (en) * 2000-07-13 2002-03-31 Upjohn Co OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
MXPA01013257A (en) * 2001-12-18 2003-06-25 Arturo Jimenez Bayardo Rofecoxib ophthalmic suspension for the treatment of ocular inflammation and pain.
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
WO2005099715A2 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd. Treatment of ophthalmic conditions with mineralcorticoids
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
EP2661264B1 (en) * 2011-01-07 2018-12-05 Allergan, Inc. Melanin modification compositions and methods of use
EP2667875A4 (en) * 2011-01-24 2014-07-30 Inceptum Res & Therapeutics Inc Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53127832A (en) * 1977-04-11 1978-11-08 Teijin Ltd Antiphkogistics for oral administration containing thiaprostaglandins
GB2135881A (en) * 1983-03-02 1984-09-12 Erba Farmitalia Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
GB8625325D0 (en) * 1986-10-22 1986-11-26 Glaxo Group Ltd Chemical compounds
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
WO1991016895A1 (en) * 1990-05-03 1991-11-14 G.D. Searle & Co. Pharmaceutical composition
WO1991016886A1 (en) * 1990-05-03 1991-11-14 G.D. Searle & Co. Pharmaceutical composition containing ibuprofen and a prostaglandin
PT740650E (en) * 1994-01-28 2004-10-29 Univ Kentucky Res Found CO-DRUGS AS A METHOD OF CONTROLLED DRUG ADMINISTRATION
SE9702706D0 (en) * 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side effects for the treatment of glaucoma

Also Published As

Publication number Publication date
AU1435000A (en) 2000-05-22
CA2349427A1 (en) 2000-05-11
AU758973B2 (en) 2003-04-03
EP1126835A1 (en) 2001-08-29
JP2002528491A (en) 2002-09-03
WO2000025771A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
SE9803761D0 (en) Method to avoid increased iridial pigmentation during prostaglandin treatment
DE69930252D1 (en) USE OF TETRACYCLINES TO TREAT MEASURES OF MEIBOPLE DRUGS
DK0969813T3 (en) Topical pharmaceutical composition comprising a cholinergic or calcium channel blocking agent
EA200401043A1 (en) Treatment of benign prostatic hyperplasia by the selective modulator of the androgen receptor (sarm)
BRPI0009956A (en) non-aqueous pharmaceutical composition for dermatological use comprising calcipotriol and betamethasone, and use thereof
CY1111872T1 (en) COMPOSITIONS FOR HYPOTHESIS (PROSTAGLANDIN) AND TIMOLOLIS - RELATED METHODS OF USE
DE69021214D1 (en) ORAL COMPOSITION FOR THE TREATMENT OF INTESTINAL FLAMMABLE DISEASES.
TR200002784T2 (en) Type 5 and type 3 17beta-Hydroxysteroid dehydrogenase inhibitors and methods for their use
DE60316779D1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF BZW. PREVENTION OF PAIN
DK1206261T3 (en) Pharmaceutical preparations comprising clavanoic acid or derivatives thereof for the treatment of behavioral diseases
DE69329856D1 (en) ESTER DERIVATIVES OF 4-AZA STEROIDS
BR9813767A (en) Process and composition for treating glc1a glaucoma
NO20034204L (en) Pharmaceutical combinations for the treatment of cancer
ATE212351T1 (en) ANDROSTENE DERIVATIVES
DE69935720D1 (en) DIAMINO-PROPANOL COMPOUNDS FOR THE TREATMENT OF ISCHEMAS
ATE201597T1 (en) ADMINISTRATION OF RILUZOLE FOR THE TREATMENT OF NEURO-AIDS
ATE245452T1 (en) HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS
DE60227278D1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF LESIONS OF SKIN AND MICE AND THESE METHOD AND KITS
ATE226014T1 (en) PROPHYLACTIC TREATMENT OF ALLERGIC CONTACT DERMATITIS
ATE241363T1 (en) COMBINATION PREPARATIONS CONTAINING UNSATURATED FATTY ACID AND STEROIDS FOR THE TREATMENT OF INFLAMMATION
KR950016760A (en) Hemorrhoids Treatment
DE69935526D1 (en) SUPRAMOLECULAR COMPLEX-CONTAINING MEDICAMENTS
ATE230609T1 (en) METHOD FOR TREATING INFLAMMATION AND COMPOSITIONS THEREFOR
DE60026491D1 (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
HUP9801022A2 (en) Use of aldose reductase inhibitor in preventing or reversing diabetic cardiomyopathy